What are the length thresholds for nucleotide and amino acid sequences requiring a “Sequence Listing”?

Source: FAQ (MPEP-Based)BlueIron Update: 2024-09-30 10 Rules5 Related FAQs This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This is information only: it is not legal advice. According to MPEP 2422.01, the length thresholds for nucleotide and…

Read More

What are the requirements for sequence disclosures in biotechnology patent applications?

Source: FAQ (MPEP-Based)BlueIron Update: 2024-09-30 10 Rules5 Related FAQs This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This is information only: it is not legal advice. MPEP 2401 introduces the requirements for sequence disclosures in biotechnology…

Read More

What is the significance of SEQ ID NO in patent applications with large numbers of nucleotide sequences?

Source: FAQ (MPEP-Based)BlueIron Update: 2024-09-30 10 Rules5 Related FAQs This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This is information only: it is not legal advice. SEQ ID NO plays a crucial role in patent applications…

Read More

How are restriction requirements handled for nucleotide sequence inventions in national applications?

Source: FAQ (MPEP-Based)BlueIron Update: 2024-09-30 10 Rules5 Related FAQs This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This is information only: it is not legal advice. For national applications filed under 35 U.S.C. 111(a), the handling…

Read More

How should sequences with defined regions separated by undisclosed gaps be represented in a Sequence Listing XML?

Source: FAQ (MPEP-Based)BlueIron Update: 2024-09-30 10 Rules5 Related FAQs This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This is information only: it is not legal advice. The MPEP 2412.05(e) provides specific guidance on how to represent…

Read More

How are sequences with known numbers of ‘n’ or ‘X’ residues between defined regions represented in a Sequence Listing XML?

Source: FAQ (MPEP-Based)BlueIron Update: 2024-09-30 10 Rules5 Related FAQs This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This is information only: it is not legal advice. According to MPEP 2412.05(e), sequences with known numbers of ‘n’…

Read More

How should a sequence constructed from non-contiguous segments be represented in a Sequence Listing XML?

Source: FAQ (MPEP-Based)BlueIron Update: 2024-09-30 10 Rules5 Related FAQs This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This is information only: it is not legal advice. According to MPEP 2412.05(e), a sequence constructed as a single…

Read More